Fasting glucose increased in the tesamorelin group at 2 weeks ( mean change , 9 mg/dL [ 95 % CI , 5-13 mg/dL ] vs 2 mg/dL [ 95 % CI , -3 to 8 mg/dL ] in the placebo group ; treatment effect , 7 mg/dL [ 95 % CI , 1-14 mg/dL ] ; P = .03 ) , but changes at 6 months in fasting glucose ( mean change , 4 mg/dL [ 95 % CI , -2 to 10 mg/dL ] with tesamorelin vs 2 mg/dL [ 95 % CI , -4 to 7 mg/dL ] with placebo ; treatment effect , 2 mg/dL [ 95 % CI , -6 to 10 mg/dL ] ; P = .72 overall across time points ) and 2-hour glucose ( mean change , -1 mg/dL [ 95 % CI , -18 to 15 mg/dL ] vs -8 mg/dL [ 95 % CI , -24 to 8 mg/dL ] , respectively ; treatment effect , 7 mg/dL [ 95 % CI , -16 to 29 mg/dL ] ; P = .53 overall across time points ) were not significant .